Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

154.90 -2.89 (-1.83%)

Delayed Quote Updated: 1:43 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗

March 05, 2026

BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms.

Via Stocktwits

Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗

March 05, 2026

Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.

Via Stocktwits

Topics Artificial Intelligence

DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise ↗

March 04, 2026

On Stocktwits, retail sentiment around DAWN stock stayed within the ‘extremely bullish’ territory over the past 24 hours.

Via Stocktwits

Topics Economy

IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗

March 04, 2026

Piper Sandler raised the firm's price target on ImmunityBio to $12 from $7 and kept an ‘Overweight’ rating on the shares.

Via Stocktwits

Topics Intellectual Property

Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗

March 02, 2026

The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug.

Via Stocktwits

Why Did QURE Stock Almost Halve Pre-Market Today? ↗

March 02, 2026

uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.

Via Stocktwits

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction ↗

February 26, 2026

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

Via Stocktwits

IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗

February 26, 2026

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Via Stocktwits

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗

February 25, 2026

The company said it has enrolled patients in its late-stage program ahead of schedule.

Via Stocktwits

Topics Earnings

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗

February 25, 2026

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

Via Stocktwits

Topics Artificial Intelligence

Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗

February 24, 2026

According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024.

Via Stocktwits

Topics Artificial Intelligence Earnings

Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗

February 24, 2026

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

Via Stocktwits

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder ↗

February 23, 2026

The company applied for approval of the gene therapy in the treatment of Glycogen Storage Disease Type Ia or Von Gierke disease.

Via Stocktwits

ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗

February 20, 2026

ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time.

Via Stocktwits

ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? ↗

February 20, 2026

Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.

Via Stocktwits

Topics Earnings Intellectual Property

GRAL Stock Slumps After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses ↗

February 19, 2026

The trial did not show a statistically significant reduction in Stage III-IV cancer diagnoses, the company said.

Via Stocktwits

Topics Artificial Intelligence Death

ARDX Stock Slips After Hours As Q4 Earnings Disappoint: Retail Sees Ibsrela Driving Outperformance In Time ↗

February 19, 2026

The company reported no earnings for the fourth quarter, compared to an analyst estimate of $0.01 per share.

Via Stocktwits

Topics Artificial Intelligence

ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗

February 19, 2026

The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.

Via Stocktwits

SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition ↗

February 18, 2026

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Via Stocktwits

IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally ↗

February 18, 2026

The European Commission granted conditional marketing authorization to ImmunityBio’s Anktiva, implying that it wants more data from the company.

Via Stocktwits

IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗

February 17, 2026

The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks.

Via Stocktwits

IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU ↗

February 13, 2026

Retail investors are now looking forward to a full approval of Anktiva in the EU for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.

Via Stocktwits

RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty ↗

February 13, 2026

Ultragenyx said on Thursday that the FDA has again refused approval for UX111 in the treatment of Sanfilippo syndrome type A.

Via Stocktwits

VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗

February 11, 2026

The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.

Via Stocktwits

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?

Via The Motley Fool

Topics Artificial Intelligence

Sector Alert: 4 Healthcare ETFs Poised for Explosive Growth Now ↗

February 11, 2026

Healthcare stocks have lagged the market for years, but 2026 is looking much better.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Why Did UPB Stock Pop 20% In Pre-Market Today? ↗

February 11, 2026

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

Via Stocktwits

Why Did RGNX Shares Plummet 19% After-Hours Today? ↗

February 09, 2026

REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial.

Via Stocktwits

MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products ↗

February 04, 2026

According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.

Via Stocktwits

Topics Artificial Intelligence

RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? ↗

January 28, 2026

REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.